Change in plasma gelsolin level after traumatic brain injury

Journal of Trauma and Acute Care Surgery

Volumn 72, Issue 2, 2012, Pages 491-496

  Xu, Jin Fang ^a   Liu, Wei Guo ^a   Dong, Xiao Qiao ^b   Yang, Song Bin ^c   Fan, Jing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c Shengzhou People's Hospital   (China)

Author keywords

Gelsolin; Mortality; Prognosis; Traumatic brain injury

Indexed keywords

GELSOLIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPERTENSIVE FACTOR; INFUSION FLUID; MANNITOL; BIOLOGICAL MARKER;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; CAUSE OF DEATH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLASGOW COMA SCALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROSURGERY; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PHYSIOTHERAPY; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; TRAUMATIC BRAIN INJURY; ADOLESCENT; AGED; BLOOD; BRAIN INJURY; CASE CONTROL STUDY; CHILD; MIDDLE AGED; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN INJURIES; CASE-CONTROL STUDIES; CHILD; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GELSOLIN; GLASGOW COMA SCALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 84860600814     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e318226ec39     Document Type: Article

References (41)

1. Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL, Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci. 2004;61:2614-2623
2. Ito H, Kambe H, Kimura Y, et al. Depression of plasma gelsolin level during acute liver injury. Gastroenterology. 1992;102:1686-1692.
3. Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med. 1997;25:594-598.
4. Huang S, Rhoads SL, DiNubile MJ. Temporal association between serum gelsolin levels and clinical events in a patient with severe falciparum malaria. Clin Infect Dis. 1997;24:951-954.
5. Dahl B, Schiødt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin is reduced in trauma patients. Shock. 1999;12:102-104.
6. Christofidou-Solomidou M, Scherpereel A, Solomides CC, et al. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung. 2002;180:91-104.
7. Rothenbach PA, Dahl B, Schwartz JJ, et al. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol. 2004;96:25-31.
8. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. 2007;35:849-855.
9. Mounzer KC, Moncure M, Smith YR, Dinubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med. 1999;160:1673-1681.
10. Lee PS, Drager LR, Stossel TP, Moore FD, Rogers SO. Relationship of plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg. 2006;243:399-403.
11. DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood. 2002;100:4367-4371.
12. Spiotta AM, Stiefel MF, Gracias VH, et al. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. J Neurosurg. 2010;113:571-580.
13. Juul N, Morris GF, Marshall SB, Marshall LF. Intracranial hypertension and cerebral perfusion pressure: influence on neurological deterioration and outcome in severe head injury. The Executive Committee of the International Selfotel Trial. J Neurosurg. 2002;92:1-6.
14. Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang MC. Relationship of early hyperglycemia to mortality in trauma patients. J Trauma. 2004;56:1058-1062.
15. Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology. 2005;64:1348-1353.
16. Marshall LF, Marshall SB, Klauber MR, van Berkum Clark M. A new classification of head injury based on computerized tomography. J Neurosurg. 1991;75:S14-S20.
17. Moppett IK. Traumatic brain injury. assessment, resuscitation and early management. Br J Anaesth. 2007;99:18-31.
18. Gordon E, von Holst H, Rudehill A. Outcome of head injury in 2298 patients treated in a single clinic during a 21-year period. J Neurosurg Anesthesiol. 1995;7:235-247.
19. Nakamura N, Yamaura A, Shigemori M, et al. Final report of the Japan Neurotrauma Data Bank project 1998-2001: 1,002 cases of traumatic brain injury. Neurol Med Chir (Tokyo). 2006;46:567-574.
20. Petzold A, Green AJ, Keir G, et al. Role of serum S100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study. Crit Care Med. 2002;30:2705-2710.
21. Lesko MM, Woodford M, White L, O'Brien SJ, Childs C, Lecky FE. Using Abbreviated Injury Scale (AIS) codes to classify Computed Tomography (CT) features in the Marshall System. BMC Med Res Methodol. 2010;10:72.
22. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med. 1992;326:1335-1341.
23. Lind SE, Smith DB, Janmey PA, Stossel TP. Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis. 1988;138:429-434.
24. Wang H, Cheng B, Chen Q, et al. Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit Care. 2008;12:R106.
25. Vos PE, Jacobs B, Andriessen TM, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology. 2010;75:1786-1793.
26. Timofeev I, Carpenter KL, Nortje J, et al. Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patients. Brain. 2011;134:484-494.
27. Bernard F, Al-Tamimi YZ, Chatfield D, Lynch AG, Matta BF, Menon DK. Serum albumin level as a predictor of outcome in traumatic brain injury: potential for treatment. J Trauma. 2008;64:872-875.
28. Yin HL, Stossel TP. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium-dependent regulatory protein. Nature. 1979;281:583-586.
29. Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature. 1986;323:455-458.
30. Janmey PA, Lind SE. Capacity of human serum to depolymerize actin filaments. Blood. 1987;70:524-530.
31. Kwiatkowski DJ, Mehl R, Izumo S, Nadal-Ginard B, Yin HL. Muscle is the major source of plasma gelsolin. J Biol Chem. 1988;263:8239-8243.
32. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest. 1986;78:736-472.
33. Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA. 1990;87:1381-1385.
34. Rosengart MR, Arbabi S, Bauer GJ, Garcia I, Jelacic S, Maier RV. The actin cytoskeleton: an essential component for enhanced TNFalpha production by adherent monocytes. Shock. 2002;17:109-113.
35. Bucki R, Georges PC, Espinassous Q, et al. Inactivation of endotoxin by human plasma gelsolin. Biochemistry. 2005;44:9590-9597.
36. Goetzl EJ, Lee H, Azuma T, Stossel TP, Turck CW, Karliner JS. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem. 2002;275:14573-14578.
37. Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol. 2007;292:C1323-C1330.
38. Christofidou-Solomidou M, Scherpereel A, Solomides CC, et al. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med. 2002;50:54-60.
39. Yildirim F, Gertz K, Kronenberg G, et al. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol. 2008;210:531-542.
40. Endres M, Fink K, Zhu J, et al. Neuroprotective effects of gelsolin during murine stroke. J Clin Invest. 1999;103:347-354.
41. Güntert A, Campbell J, Saleem M, et al. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis. 2010;21:585-596.